The ALPP Knockout 143B Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ALPP gene in the human 143B osteosarcoma cell line. This polyclonal knockout product provides a genetically heterogeneous loss-of-function model suitable for investigating the functional role of placental alkaline phosphatase (ALPP) in a bone cancer context. The cells retain the background genetic characteristics of the 143B line while exhibiting targeted disruption of the ALPP locus, enabling robust comparative studies against wild-type controls.
The host cell line, 143B, is a highly tumorigenic human osteosarcoma cell line harboring a mutant TP53 gene. Widely established as a model for bone cancer research, 143B cells are extensively utilized in studies of osteosarcoma biology, bone metastasis, and xenograft tumor growth. Their aggressive phenotype and consistent in vivo tumor formation make them a valuable platform for evaluating gene function in the context of osteosarcoma and for preclinical drug assessment.
ALPP encodes a glycosylphosphatidylinositol (GPI)-anchored alkaline phosphatase enzyme that catalyzes the dephosphorylation of extracellular substrates. Transcriptional regulation of ALPP is mediated by upstream factors such as the AP-2 transcription factor, Sp1, and Wnt/??-catenin signaling. Functionally, ALPP modulates signaling through the PI3K/AKT and MAPK/ERK pathways, as evidenced by changes in AKT and ERK phosphorylation levels. Downstream, ALPP influences cyclin D1 expression and cell cycle progression. The enzyme exists as a homodimer and interacts with the GPI-anchor synthesis machinery and caveolin-1, implicating its localization in lipid rafts and potential roles in signal compartmentalization.
In the 143B osteosarcoma background, disruption of ALPP is expected to attenuate extracellular dephosphorylation activity, leading to altered PI3K/AKT and MAPK/ERK signaling cascades. This molecular perturbation is predicted to impact cell proliferation and migration, two hallmark processes in osteosarcoma progression. Consequently, the ALPP knockout polyclonal cells serve as a pertinent model for dissecting the contribution of ALPP to the malignant phenotype of osteosarcoma, including its potential involvement in tumor growth, metastasis, and response to therapeutic agents.
These ALPP-knockout polyclonal cells are suitable for a wide range of applications, including functional characterization of ALPP in osteosarcoma, evaluation of ALPP as a tumor marker, and elucidation of signal transduction mechanisms. Representative assays include western blotting to confirm loss of ALPP protein, alkaline phosphatase activity assays, RT-qPCR for transcript analysis, MTT or CCK-8 proliferation assays, Transwell migration/invasion assays, phospho-signaling analysis (e.g., phospho-AKT, phospho-ERK), flow cytometry for cell cycle distribution, and xenograft tumor growth studies. The model also supports drug sensitivity and resistance testing. For further technical information, please contact Ascent Research.
